Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugstore.com

This article was originally published in The Rose Sheet

Executive Summary

Online drugstore expects to acquire 800,000-900,000 new customers in 2002, Bellevue, Wash. company reports during 1fourth quarter and year-end sales and earnings call Jan. 29. Firm notes 225,000 new customers joined the site in Q4, bringing total customer base to 2.4 mil. Net sales for fiscal 2001 reached $145.3 mil., up 32.1% from prior-year period. Fourth quarter sales were $43.5 mil., an increase of 20.2%, company says. Drugstore.com reports a loss of $282.8 mil. for the year, including a $178 mil. restructuring charge, compared to $193 mil. loss a year ago. In Q4, firm recorded loss of $182.9 mil. (including a $163 mil. charge) compared to a loss of $43.2 mil. in 2000 period. Drugstore.com expects to achieve EBITDA profitability by 2003 (2"The Rose Sheet" Jan. 14, 2002, p. 9)...

You may also be interested in...



Drugstore.com Sales Gains, Cost Reductions Expected To Yield Profit By 2003

Online retailer drugstore.com sets $305 mil.-$315 mil. revenue target for 2003 - a level more than double the firm's 2001 sales - as part of an accelerated growth initiative

Probiotics’ Efficacy Too Specific For General Look In ’60 Minutes’ Segment Critical Of Category

A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.

Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

UsernamePublicRestriction

Register

MT142350

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel